Literature DB >> 23134154

Uncovered self-expandable metallic stent placement as a first-line palliative therapy in unresectable malignant duodenal obstruction.

Hyung Su Ahn1, Su Jin Hong, Jong Ho Moon, Bong Min Ko, Hyun Jong Choi, Jae Pil Han, Jin Seok Park, Myung Soo Kang, Joo Young Cho, Joon Seong Lee, Moon Sung Lee.   

Abstract

OBJECTIVE: To report treatment outcomes and complications of uncovered self-expandable metallic stents (SEMS) as a first-line therapy for inoperable malignant duodenal obstructions in our hospital.
METHODS: A retrospective analysis was performed in patients who had undergone placement of uncovered SEMS as a first-line therapy for inoperable malignant duodenal obstruction from August 2001 to July 2011. Treatment outcomes and complications of the procedures were investigated.
RESULTS: In total, 47 patients (25 men; mean age 65 years) underwent the procedure. The technical and clinical success rates were 93.6% and 83.0%, respectively. Early complications occurred in 8 patients, including two guidewire-induced micro-perforations and six pancreatitis. All these 8 patients recovered with conservative treatment. Six late complications requiring additional procedures consisted of five stent occlusions due to tumor ingrowth and one stent migration. Four stent occlusions and one migration were treated by the placement of an additional covered stent and the remaining case was treated by balloon dilatation. The median primary stent patency period and median survival period after primary stent placement were 103 days and 131 days, respectively.
CONCLUSIONS: Uncovered SEMS placement is effective as a first-line palliative therapy for inoperable malignant duodenal obstruction. Complications such as stent occlusion or migration can be easily managed with additional covered SEMS.
© 2012 The Authors. Journal of Digestive Diseases © 2012 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23134154     DOI: 10.1111/j.1751-2980.2012.00644.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  6 in total

1.  Comparison between uncovered and covered self-expandable metal stent placement in malignant duodenal obstruction.

Authors:  Ji Won Kim; Ji Bong Jeong; Kook Lae Lee; Byeong Gwan Kim; Dong Won Ahn; Jae Kyung Lee; Su Hwan Kim
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  SEMS vs cSEMS in duodenal and small bowel obstruction: high risk of migration in the covered stent group.

Authors:  Oliver Waidmann; Jörg Trojan; Mireen Friedrich-Rust; Christoph Sarrazin; Wolf Otto Bechstein; Frank Ulrich; Stefan Zeuzem; Jörg Gerhard Albert
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

3.  Fracture of a Self-expandable Metallic Stent Inserted for Malignant Gastric Outlet Obstruction.

Authors:  Makoto Kadokura; Yumi Takenaka; Hiroki Yoda; Tomoki Yasumura; Tetsuya Okuwaki; Keisuke Tanaka; Fumitake Amemiya
Journal:  Intern Med       Date:  2020-11-30       Impact factor: 1.271

4.  A Multicenter Randomized Controlled Trial of Malignant Gastric Outlet Obstruction: Tailored Partially Covered Stents (Placed Fluoroscopically) versus Standard Uncovered Stents (Placed Endoscopically).

Authors:  Ding Shi; Feng Ji; Yin-Su Bao; Yong-Pan Liu
Journal:  Gastroenterol Res Pract       Date:  2014-12-24       Impact factor: 2.260

5.  Comparison of big funnel and individualized stents for management of stomach cancer with gastric outlet obstruction.

Authors:  Ding Shi; Jianping Liu; Xujun Hu; Yongpan Liu; Feng Ji; Yinsu Bao; Daxin Guo
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

6.  Big End Double-Layer Stents for the Treatment of Gastric Outlet Obstruction Caused by Stomach Cancer.

Authors:  Ding Shi; Dong Wu; Yongpan Liu; Feng Ji; Yinsu Bao
Journal:  Gastroenterol Res Pract       Date:  2019-07-01       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.